Our Pricing

Orlistat vs Wegovy: Your Starter Dose Comparison

Published on: June 03, 2026

Choosing between orlistat vs Wegovy starter dose UK options requires understanding how each treatment works and what to expect during your first weeks. At Cured Pharmacy, our UK-registered clinical team helps patients navigate this decision with transparent pricing, expert guidance, and genuine UK-licensed medications delivered discreetly to your door.

Understanding Orlistat vs Wegovy Starter Dose Protocols

Orlistat and Wegovy represent fundamentally different approaches to weight management, reflected in their distinct starter dose protocols. Orlistat (available as 60mg over-the-counter or 120mg prescription-strength) works in your digestive system by blocking approximately 25% of dietary fat absorption [1]. The standard starting dose is 120mg taken three times daily with meals, and this dose remains constant throughout treatment — there's no titration required.

Wegovy (semaglutide 2.4mg) follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects whilst your body adapts to the medication [2]. The starter dose begins at just 0.25mg once weekly for the first four weeks, then gradually increases monthly through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg. This graduated approach, validated in the STEP clinical trial programme, significantly improves tolerability compared to starting at higher doses [2].

The choice between these starter protocols often depends on your medical history, weight loss goals, and tolerance for potential side effects. Superintendent pharmacist Tarun Kumar notes that patients with previous experience of GLP-1 medications typically adapt more quickly to Wegovy's escalation schedule, whilst those preferring a simpler regimen may initially favour orlistat's fixed dosing.

How Each Treatment Works: Mechanisms of Action

Orlistat functions as a lipase inhibitor, binding to gastric and pancreatic enzymes in your digestive tract to prevent them from breaking down dietary triglycerides into absorbable free fatty acids [1]. This mechanism is entirely local to your gut — orlistat is minimally absorbed into your bloodstream, with less than 1% systemic bioavailability. The unabsorbed fat passes through your system and is eliminated, resulting in approximately 25% reduction in fat absorption when taken as prescribed.

Wegovy operates through a completely different pathway as a glucagon-like peptide-1 (GLP-1) receptor agonist [2]. Semaglutide mimics the action of natural GLP-1, a hormone your body produces after eating. It works centrally in the brain to reduce appetite and food cravings, slows gastric emptying to increase satiety, and improves glucose-dependent insulin secretion. In the STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks at the 2.4mg maintenance dose, compared to 2.4% with placebo [2].

These distinct mechanisms mean the treatments suit different patient profiles. Orlistat requires dietary modification to minimise side effects — keeping fat intake below 15g per meal — whilst Wegovy's appetite suppression often naturally reduces caloric intake without rigid meal planning requirements.

Choosing Based on Your Lifestyle

Your daily routine significantly influences which starter dose protocol fits best. Orlistat requires taking capsules three times daily with main meals, demanding consistent meal timing and planning. Wegovy's once-weekly injection offers greater flexibility — many patients find injecting the same day each week (often Sunday evening) integrates seamlessly into their schedule. Both medications require clinical assessment by a UK prescriber before dispensing, ensuring the chosen treatment aligns with your medical history and weight loss objectives.

Orlistat vs Wegovy Starter Dose: Expected Weight Loss Results

Clinical trial data reveals substantial differences in weight loss outcomes between these treatments during the initial months. With orlistat 120mg three times daily, patients in the XENDOS study achieved an average 5.8kg weight loss over the first six months when combined with lifestyle modifications [1]. Weight loss typically plateaus after 6-12 months, with average total body weight reduction of approximately 5-10% in adherent patients.

Wegovy demonstrates more pronounced effects even during the starter dose escalation phase. In the STEP 1 trial, participants lost an average of 6% body weight during the first 16 weeks whilst still titrating up through the lower doses [2]. By week 68 at the 2.4mg maintenance dose, average weight loss reached 14.9% of initial body weight — nearly three times the reduction seen with orlistat in comparable timeframes [2]. Importantly, approximately 86% of Wegovy-treated patients achieved at least 5% weight loss, compared to roughly 60% with orlistat in head-to-head comparisons.

These outcomes reflect controlled trial conditions with dietary counselling and regular monitoring. Real-world results vary based on adherence, lifestyle modifications, baseline BMI, and individual metabolic factors. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, helping optimise outcomes regardless of which medication you're prescribed.

Setting Realistic Expectations

Neither medication produces immediate results — orlistat requires 2-3 months to demonstrate meaningful weight loss, whilst Wegovy's effects become more apparent as you progress through the dose escalation to higher strengths. Your UK prescriber will discuss realistic timelines and weight loss targets during your consultation, typically recommending at least 12 weeks before evaluating treatment efficacy. If you haven't achieved at least 5% weight loss after three months on orlistat or six months on Wegovy, your prescriber may suggest adjusting your treatment plan.

Side Effects: What to Expect During Starter Doses

Orlistat's side effects stem directly from its mechanism of preventing fat absorption. The most common effects are gastrointestinal: oily spotting, flatulence with discharge, urgent bowel movements, and fatty or oily stools [1]. These symptoms occur in approximately 15-30% of patients and are directly proportional to dietary fat intake. Keeping fat consumption below 15g per meal significantly reduces these effects. Because orlistat isn't systemically absorbed, it doesn't cause nausea, headaches, or other central side effects common with appetite suppressants.

Wegovy's starter dose escalation specifically aims to minimise gastrointestinal side effects, but they remain the most commonly reported adverse events. During the 0.25mg and 0.5mg starter doses, approximately 44% of patients experience nausea, 30% report diarrhoea, and 24% have vomiting in clinical trials [2]. These effects typically peak 2-3 days after injection and diminish as your body adapts. The gradual dose increases allow most patients to develop tolerance — side effects at each new dose level tend to be milder than the previous increase. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods during the first days after injection helps manage symptoms.

Serious side effects are rare with both medications but require immediate medical attention. Orlistat can interfere with absorption of fat-soluble vitamins (A, D, E, K), and rare cases of severe liver injury have been reported [1]. Wegovy carries warnings for thyroid C-cell tumours (based on rodent studies), pancreatitis, gallbladder disease, and hypoglycaemia in patients taking diabetes medications [2]. Your prescriber will review your complete medical history to identify any contraindications before prescribing.

Wegovy Starter Dose UK: Pricing and Availability at Cured Pharmacy

Wegovy is available at Cured Pharmacy with transparent upfront pricing visible before you complete your consultation. The treatment starts from £79.00 per month, representing competitive UK pricing compared to typical market rates. This includes your medication, free online consultation with a UK-registered prescriber, and discreet next-day delivery across the UK. All Wegovy pens are genuine UK-licensed products sourced through MHRA-approved channels.

The starter dose pack contains four 0.25mg pre-filled pens for your first month, followed by monthly supplies at progressively higher strengths as you titrate upward. Your prescriber determines the appropriate escalation schedule based on your tolerance and response. Unlike some providers, Cured Pharmacy displays exact pricing before you begin your consultation — no hidden fees or surprise charges at checkout. We guarantee the lowest prices in the UK, and if you find genuine UK-licensed Wegovy cheaper elsewhere, we'll match it.

Orlistat 120mg is also available through Cured Pharmacy following clinical assessment, offering a lower-cost alternative for patients who prefer oral medication or have contraindications to GLP-1 treatments. Both medications require a valid UK prescription, which our clinical team can issue following your free online consultation that takes under three minutes to complete. Simply select your preferred treatment, answer the medical questionnaire honestly, and a UK prescriber will review your assessment typically within 24 hours.

Starting Your Weight Loss Journey

Beginning treatment is straightforward at Cured Pharmacy. Click 'Start Assessment' on the Wegovy product page, complete the brief medical questionnaire covering your weight history, current medications, and relevant health conditions, then submit for prescriber review. If approved, your medication ships the same day for next-day delivery in 100% discreet packaging. Our clinical team remains available on (+44) 116 4646009 if you have questions during treatment, and you can message your prescriber through your patient account for ongoing support.

Which Starter Dose Protocol Is Right for You?

Several factors influence whether orlistat or Wegovy represents the better choice for your weight loss journey. Consider orlistat if you prefer oral medication, want to avoid injections, have a BMI between 28-35 with comorbidities or over 30 without, and are willing to follow a reduced-fat diet consistently. Orlistat suits patients seeking a non-systemic option without central nervous system effects, and those who've had previous adverse reactions to GLP-1 medications.

Wegovy typically proves more appropriate for patients with BMI over 30 (or 27 with weight-related conditions), those who've tried orlistat or other weight loss medications without adequate response, individuals comfortable with once-weekly injections, and patients seeking more substantial weight loss outcomes. The STEP trials demonstrated Wegovy's particular efficacy in patients with obesity-related comorbidities including type 2 diabetes, hypertension, and dyslipidaemia [2].

Contraindications play a crucial role in this decision. Orlistat is contraindicated in chronic malabsorption syndromes, cholestasis, and pregnancy [1]. Wegovy cannot be prescribed if you have personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous serious hypersensitivity to semaglutide, or if you're pregnant or breastfeeding [2]. Your UK prescriber will conduct a thorough assessment to determine medical suitability for either treatment, potentially suggesting alternatives like Saxenda or Mysimba if neither orlistat nor Wegovy is appropriate.

Making an Informed Decision

The choice between orlistat vs Wegovy starter dose protocols isn't purely clinical — it involves personal preferences around injection versus oral medication, tolerance for different side effect profiles, budget considerations, and lifestyle factors. During your consultation at Cured Pharmacy, be candid about your concerns, previous weight loss attempts, and treatment preferences. Our prescribers take a patient-centred approach, recommending the treatment most likely to succeed based on your individual circumstances rather than defaulting to any particular medication. Both treatments require commitment to lifestyle modifications including balanced nutrition and regular physical activity for optimal results.

Scientific References

1. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
4. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
5. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.